相似文献
1
AAV Immunogenicity: New Answers Create New Questions.
Mol Ther. 2018 Nov 7;26(11):2538-2539. doi: 10.1016/j.ymthe.2018.10.004. Epub 2018 Oct 23.
2
Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
Hum Gene Ther. 2017 Nov;28(11):1061-1074. doi: 10.1089/hum.2017.150.
3
Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors.
J Immunol. 2012 Jun 15;188(12):6418-24. doi: 10.4049/jimmunol.1200620. Epub 2012 May 16.
4
CD8(+) T-cell responses to adeno-associated virus capsid in humans.
Nat Med. 2007 Apr;13(4):419-22. doi: 10.1038/nm1549. Epub 2007 Mar 18.
5
Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.
Virology. 2004 Dec 20;330(2):375-83. doi: 10.1016/j.virol.2004.10.012.
6
Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.
J Immunother. 2015 Sep;38(7):292-8. doi: 10.1097/CJI.0000000000000093.
7
Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy.
Hum Gene Ther. 2017 Apr;28(4):328-337. doi: 10.1089/hum.2016.172. Epub 2016 Dec 29.
8
Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.
J Virol. 2000 Oct;74(19):9281-93. doi: 10.1128/jvi.74.19.9281-9293.2000.
9
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Mol Ther. 2007 Apr;15(4):792-800. doi: 10.1038/sj.mt.6300090. Epub 2007 Jan 23.
10
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
Gene Ther. 2008 Jun;15(11):808-16. doi: 10.1038/gt.2008.54. Epub 2008 Apr 3.
引用本文的文献
1
Nanoparticle-based Gene Therapy for Neurodegenerative Disorders.
Mini Rev Med Chem. 2024;24(19):1723-1745. doi: 10.2174/0113895575301011240407082559.
2
Machine-learning-guided Directed Evolution for AAV Capsid Engineering.
Curr Pharm Des. 2024;30(11):811-824. doi: 10.2174/0113816128286593240226060318.
3
What's new and what's next for gene therapy in Pompe disease?
Expert Opin Biol Ther. 2022 Sep;22(9):1117-1135. doi: 10.1080/14712598.2022.2067476. Epub 2022 Apr 27.
4
Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues.
Mol Ther Methods Clin Dev. 2019 Jun 4;14:77-89. doi: 10.1016/j.omtm.2019.05.012. eCollection 2019 Sep 13.
本文引用的文献
1
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.
J Clin Invest. 2018 Dec 3;128(12):5267-5279. doi: 10.1172/JCI122372. Epub 2018 Oct 22.
2
Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
JCI Insight. 2018 Jun 21;3(12). doi: 10.1172/jci.insight.120474.
3
Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8 T cells.
Blood. 2017 Jun 15;129(24):3184-3195. doi: 10.1182/blood-2016-11-751040. Epub 2017 May 3.
4
The Balance between CD8 T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose.
Mol Ther. 2017 Apr 5;25(4):880-891. doi: 10.1016/j.ymthe.2017.02.014. Epub 2017 Mar 9.
Zotero 插件